Cancer Drug Prices Set to Drop? Centre Caps Trade Margins at 30% in Major Relief for Patients

The Central Government has approved a 30% cap on trade margins for non-scheduled anti-cancer medicines in a move aimed at making cancer treatment more affordable for patients across India. Announced on October 8, 2026, the measure seeks to curb excessive mark-ups in the pharmaceutical supply chain and reduce the financial burden on families dealing with cancer.

According to the Ministry of Chemicals and Fertilizers, the initiative could lower the prices of affected medicines by up to 70% and help patients save an estimated ₹2,500 crore annually. These figures are government estimates, and actual savings will depend on the medicines covered and their existing prices

What Does the 30% Trade-Margin Cap Mean?

Trade margins are the amounts added by distributors, wholesalers and retailers as medicines move through the supply chain. Under the new measure, margins on covered non-scheduled anti-cancer drugs will be restricted to 30% of their maximum retail price (MRP).

Scheduled cancer medicines are already subject to government price controls. The new decision extends price protection to non-scheduled medicines, which were not covered by the same scheduled ceiling-price framework.

The policy is intended to address unusually high mark-ups and improve transparency in the pricing of cancer medicines.

Around 110 Cancer Medicines May Be Covered

Government reports have indicated that the measure is expected to cover approximately 110 non-scheduled anti-cancer medicines, including patented drugs as well as branded and generic formulations, from domestic and imported sources.

An expert committee under the Directorate General of Health Services has been tasked with finalising the list of medicines to be covered. The National Pharmaceutical Pricing Authority (NPPA) will oversee implementation through the applicable regulatory process.

Patients should check official price notifications to determine whether a particular medicine is covered and what its revised retail price will be.

Government Expects ₹2,500 Crore in Annual Savings

The Centre estimates that the initiative could save cancer patients around ₹2,500 crore each year. The potential price reductions could be significant for people who require expensive medicines over extended treatment periods.

Cancer treatment costs can include medicines, hospital stays, diagnostic tests, surgery and other therapies. Reducing excessive distribution margins could ease one component of these expenses, although it will not necessarily eliminate the overall financial burden of treatment.

Why Has the Government Introduced the Measure?

The decision follows concerns over steep mark-ups on certain cancer medicines and scrutiny of medicine pricing. The government has said the policy is intended to improve affordability while ensuring that essential medicines remain available.

India previously introduced a trade-margin rationalisation measure in 2019 covering 42 selected non-scheduled anti-cancer medicines. The latest initiative expands the scope of price protection.

The effectiveness of the new cap will depend on implementation, compliance by companies and distributors, and the final list of medicines covered.

What Should Cancer Patients Know?

The 30% cap does not mean that every cancer medicine will immediately become 70% cheaper. The actual reduction will vary according to the medicine’s existing price and trade margins, as well as the applicable regulatory notification.

Patients and caregivers should consult their oncologists, pharmacists or official NPPA price information before making decisions about treatment or purchases.

The government's move represents an expansion of medicine-price regulation, with the stated aim of reducing excessive trade mark-ups and improving access to cancer treatment in India.